Wells Fargo Maintains Overweight on Cytokinetics, Raises Price Target to $105
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Yanan Zhu maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $105.
Wells Fargo analyst Yanan Zhu maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $105.